A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

As interest in oncology grows, real-world data could help biopharma firms improve clinical research, reduce costs

by Brett J. Davis, General Manager & Principal | ConvergeHealth by Deloitte, Deloitte Consulting LLP

Early this year, I attended the annual J.P. Morgan Healthcare conference where investors and biopharmaceutical company executives were excited about the growth of personalized therapies—particularly in oncology. This optimism was somewhat tempered by some of the many challenges in oncology research and development (R&D) and bringing high-cost therapies to market. However, advances in digital health,

Read more

Empowered patients, value, and digital are driving us to a new health model

by Brett J. Davis, General Manager & Principal | ConvergeHealth by Deloitte, Deloitte Consulting LLP

Five years ago—recognizing that the shift to value-based, personalized health care would have a profound and transformational impact on the industry—we launched ConvergeHEALTH. Our goal was to team up with leading health care institutions, technology companies, life sciences innovators, and patient advocacy groups to create new platforms and solutions to support this transformation for the benefit of patients.

Read more

Health and research in 2019: Five trends to watch

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

There is something about a new year that gives us a clearer vantage point on the trends that might lie ahead. A new year might be an artificial demarcation point, but I use it to reflect on where the health care and innovation market is now, and where it could be headed.

The exponential promise that exists in the life sciences and health care sectors is unprecedented.

Read more

Demonstrating and rewarding value in health care

by Jeff Morgan, Managing Director, Deloitte Consulting LLP

The growing importance of real world evidence and value-based contracting programs

As the cost of health care continues to rise, life sciences companies are facing mounting pricing pressure and a growing need to continuously demonstrate the value of their products in a real-world population. These market forces are driving more and more life sciences companies to invest in new capabilities with the goal of harnessing the power of real world data (RWD) and changing how value is both demonstrated and rewarded.

Read more

Moving value-based contracting from experimentation to common practice

by Jeff Morgan, Managing Director, Deloitte Consulting LLP

As the health care world continues its shift from volume- to value-based reimbursement, value-based contracts (VBC) between life sciences companies and payers that tie the reimbursement of a product to the value it delivers are gaining traction.

The health care system is going through a volume-to-value transformation with the goal of controlling cost and improving patient outcomes.

Read more

If disruption of the health care system is inevitable, will stakeholders work together?

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

When it comes to their health care, many patients are becoming data scientists as they begin to gain access to data related to their health. In response to this data disruption, health plans, pharmaceutical companies, federal agencies, and nonprofits should develop tools and coaching services to help people get the most from their health data.

Read more